On Oct. 23, 2020, AstraZeneca announced that the clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, had resumed across the world with regulators in the US, UK, Brazil, South Africa and Japan confirming that it was safe to do so. AZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech.